

Supplementary Materials

Table S1. Compounds Used in the Training and Validation Sets.















Groups	Compound	Structure	logP ^a	MW	Classification ^b
Training set	aniline		0.9	93.13	NGTC
	aspirin		1.19	180.16	NC
	atenolol		0.16	266.34	NGTC
	bromocryptine		3.5	654.60	NGTC
	bupirone		2.63	385.50	NC
	butylated hydroxytoluene		5.54	220.35	NGTC
	captopril		0.34	217.29	NC
	carbamazepine		2.45	236.27	NGTC
	chlorpromazine		5.41	318.86	NGTC
	clozapine		3.23	326.82	NC
	cyproterone acetate		2.11	416.94	NGTC
	dantrolene		1.7	314.25	NGTC
	dapsone		0.97	248.30	NGTC
	dexamethasone		1.83	392.46	NC
	diclofenac		4.51	296.15	NC
dieldrin		2.38	377.87	NGTC	

Table S1. Cont.

















dipyridamole		1.5	504.63	NC
disulfiram		3.88	296.54	NC
famotidine		-0.64	337.45	NC
fluoxetine		4.05	309.33	NC
furosemide		2.03	330.74	NGTC
gabapentin		-1.1	171.24	NGTC
indomethacin		4.27	357.79	NC
isoniazid		-0.7	137.14	NGTC
lansoprazole		1.9	369.36	NGTC
mebendazole		2.83	295.29	NC
metformin		-0.5	129.16	NC
methotrexate		-1.85	454.44	NC
methyl dopa		-1.7	211.21	NC
metoprolol		1.88	267.36	NC
monocrotaline		-0.65	325.15	NGTC
mycophenolic acid		2.8	320.34	NC
naltrexone		1.92	341.40	NC

Table S1. Cont.















niacin		0.36	123.11	NC
nizatidine		1.1	331.46	NC
perhexiline		6.2	277.49	NC
phenobarbital		1.47	232.24	NGTC
phenylephrine		-0.31	167.21	NC
piperonyl butoxide		3.85	338.21	NGTC
raloxifene		5.2	473.58	NGTC
ranitidine		0.27	314.40	NC
retinol (vitaminA)		5.68	286.45	NC
rifampicin		2.7	822.94	NGTC
rotenone		2.9	394.14	NC
simvastatin		4.68	418.57	NGTC
sulfamethoxazole		0.89	253.28	NGTC
tetracycline		-1.3	444.43	NC
transAnethole		2.91	148.09	NC
valproic acid		2.75	144.21	NGTC
felbamate		0.3	238.24	NGTC

Table S1. Cont.
























	methapyrilene		2.87	297.85	NGTC
	amiodarone		7.57	645.31	NGTC
	diflunisal		4.44	250.20	NC
	ketoconazole		4.35	531.43	NC
	perfluorodecanoic acid		5.66	513.97	NGTC
	phenytoin		2.47	252.27	NGTC
	tannic acid		6.2	1700.17	NC
Test set	enalapril		0.07	376.45	NC
	glybenclamide		4.7	494.00	NC
	hexachlorocyclohexane		3.72	290.83	NC
	ibuprofen		3.97	206.28	NC
	nifedipine		2.2	346.33	NC
	quercetin dihydrate		0.35	302.24	NC
	rosiglitazone		2.4	357.43	NC
	troglitazone		3.6	441.54	NC

Table S1. Cont.

verapamil		3.79	454.60	NC
benzbromarone		4.95	421.97	NGTC
clofibrate		3.3	242.70	NGTC
dichloroacetate		0.92	128.94	NGTC
diethylphthalate		2.41	222.09	NGTC
ethynylestradiol		3.67	296.40	NGTC
flutamide		3.35	276.21	NGTC
pregnenolone carbonitrile		3.62	316.48	NGTC
progesterone		3.87	314.46	NGTC
tamoxifen		7.1	371.51	NGTC
WY-14643		4.37	323.05	NGTC
perfluorooctanoic acid		4.46	413.97	NGTC
benzafibrate		3.77	361.11	NGTC

^a logP of compounds were mainly derived from Experimental Properties in DRUG BANK and values colored in red indicated they were predicted by ChemBioDraw Ultra 12.0; ^b Classifications of compounds were based on a reference^[1]. NGTC stands for non-genotoxic carcinogens and NC stands for non-carcinogens.

Table S2. the performance of models constructed by different number of molecular descriptors.

The number of molecular descriptors for model	Acc.	Spec.	Sens.	AUC	MCC
4	0.761 ± 0.115	0.743 ± 0.175	0.779 ± 0.178	0.761 ± 0.115	0.540 ± 0.231
5	0.724 ± 0.117	0.700 ± 0.190	0.749 ± 0.189	0.724 ± 0.117	0.470 ± 0.238
6	0.702 ± 0.116	0.631 ± 0.198	0.774 ± 0.176	0.702 ± 0.116	0.427 ± 0.239

Figure S1. the performance of integrated models incorporating one or two gene expression probe(s) ** $p < 0.01$ (compared to integrated model incorporating two gene expression probes).





Figure S2. The performance of models for internal validation. QSAR alone model and Integrated model were evaluated by averaged Acc., Sens., Spec., AUC, MCC. ** $p < 0.01$ (compared to QSAR alone model). Microarray alone model and integrated model were also evaluated by averaged Acc., Sens., Spec., AUC, MCC. ## $p < 0.01$ (compared to integrated model).



Reference

1. Nie, A.Y.; McMillian, M.; Brandon Parker, J.; Leone, A.; Bryant, S.; Yieh, L.; Bittner, A.; Nelson, J.; Carmen, A.; Wan, J. Predictive toxicogenomics approaches reveal underlying molecular mechanisms of nongenotoxic carcinogenicity. *Mol. Carcinog.* **2006**, *45*, 914–933.